{
    "clinical_study": {
        "@rank": "82224", 
        "acronym": "ViDMe", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D", 
                "arm_group_type": "Active Comparator", 
                "description": "Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs"
            }, 
            {
                "arm_group_label": "arachides oleum raffinatum", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess whether vitamin D supplementation after surgery of a first  cutaneous malignant\n      melanoma protects against relapse of the disease."
        }, 
        "brief_title": "Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cutaneous Malignant Melanoma", 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Skin Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess whether vitamin D supplementation, in the follow up period after diagnosis and\n      surgery of a first  cutaneous malignant melanoma, has a protective effect on relapse of\n      cutaneous malignant melanoma and whether this protective effect correlates with vitamin D\n      levels in serum and vitamin D receptor (VDR) immunoreactivity in the primary tumor."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Older than 18 years and younger than 80 years of age.\n\n          2. Histologically proven malignant melanoma, stage one B (IB) to three (III) Not\n             participating in other clinical trial.\n\n          3. The only treatment for melanoma is surgical treatment.\n\n          4. Complete resection of melanoma.\n\n          5. Single primary cutaneous melanoma\n\n          6. Signed ethical committee approved informed consent\n\n          7. Serum phosphate, serum calcium at the entry of the study within normal limits of\n             laboratory reference\n\n        Exclusion criteria\n\n          1. Pregnant/lactating women or planning on becoming pregnant during the study\n\n          2. Known hypersensitivity to vitamin D or its components.\n\n          3. Pre-existing renal stone disease, chronic renal disease with glomerular filtration\n             rate (eGFR)  < 30 mL/min/1.73 m2 or renal dialysis.\n\n          4. Liver failure or chronic liver disease with liver enzymes > 2 fold upper limit of\n             normal (ULN).\n\n          5. History of parathyroid disease or granulomatous disease (TBC and sarcoidosis)\n\n          6. History of malabsorption syndrome or any medical condition that might interfere with\n             vitamin D absorption.\n\n          7. History of small intestine resection.\n\n          8. History of other malignancy  within the last 5 years except for carcinoma in situ of\n             the cervix or basal cell carcinoma or squamous cell carcinoma of the skin.\n\n          9. Chronic alcohol abuse.\n\n         10. Medical or logistic problems likely to preclude completion of the study.\n\n         11. Taking medication that predisposes to hypercalcemia (digoxin, lithium, thiazide\n             diuretics) or taking medication that would affect metabolism of vitamin D\n             (anticonvulsants, corticosteroids, H2-receptor antagonists)\n\n         12. Intake of vitamin D supplements within 6 months prior to entry of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748448", 
            "org_study_id": "2012LRDVDCM", 
            "secondary_id": "2012-002125-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D", 
                "description": "prospective interventional randomized double blind placebo controlled trail\nclinical setting (tertiary university hospital)\ninvestigator driven, no pharmaceutical sponsor\ncutaneous malignant melanoma patients\nadd- on study (placebo or vitamin D) on top of optimal standard care\n1:1 inclusion ratio (placebo:Vitamin D)\nrandomisation after informed consent and screening", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug", 
                "other_name": [
                    "D-Cure", 
                    "Cholecalciferol"
                ]
            }, 
            {
                "arm_group_label": "arachides oleum raffinatum", 
                "intervention_name": "arachides oleum raffinatum", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cutaneous malignant melanoma", 
            "Vitamin D", 
            "Cholecalciferol"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "marjan.garmyn@uzleuven.be", 
                    "last_name": "Marjan Garmyn, MD PhD", 
                    "phone": "+3216337950", 
                    "phone_ext": "37950"
                }, 
                "contact_backup": {
                    "email": "Vivien.Marasigan@uzleuven.be", 
                    "last_name": "Vivien Marasigan, MD", 
                    "phone": "+3216337950", 
                    "phone_ext": "37950"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "UZ Sint Rafael ( UZLeuven)"
                }, 
                "investigator": {
                    "last_name": "Marjan Garmyn, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Arjen Nikkels, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Chef de Service du Service Universitaire de Dermatologie"
                }, 
                "investigator": {
                    "last_name": "Arjen Nikkels, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eva Remenyik, MD; PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary", 
                        "zip": "4032"
                    }, 
                    "name": "Dep. of Dermatology, Medical and Health Science Center University of Debrecen"
                }, 
                "investigator": {
                    "last_name": "Eva Remenyik, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Hungary"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome", 
        "other_outcome": {
            "description": "Incidence and severity of adverse events will be recorded every 3 months up to final study visit.", 
            "measure": "Safety endpoints:Incidence and severity of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "study duration maximum 3,5 years"
        }, 
        "overall_contact": {
            "email": "marjan.garmyn@uzleuven.be", 
            "last_name": "Marjan Garmyn, MD, PhD", 
            "phone": "+32 16337950", 
            "phone_ext": "37950"
        }, 
        "overall_contact_backup": {
            "email": "vivien.marasigan@zleuven.be", 
            "last_name": "Vivien Marasigan, MD", 
            "phone": "+32 16337950", 
            "phone_ext": "37950"
        }, 
        "overall_official": {
            "affiliation": "Universitaire Ziekenhuizen Leuven", 
            "last_name": "Marjan Garmyn, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disease free survival will be the primary endpoint of this phase III trial. Patients are enrolled during a recruitment phase of three years maximum. Study duration for one patient is maximum 3,5 years or until relapse occurs.", 
            "measure": "Relapse free survival", 
            "safety_issue": "No", 
            "time_frame": "study duration maximum 3,5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Vitamin D levels at diagnosis will be correlated with melanoma subtype, as assessed clinically and histologically.", 
                "measure": "Melanoma subtype, as assessed clinically and histologically", 
                "safety_issue": "No", 
                "time_frame": "study duration maximum 3,5 years"
            }, 
            {
                "description": "Vitamin D levels at diagnosis will be correlated with melanoma site, as clinically recorded.", 
                "measure": "Melanoma site, as clinically recorded", 
                "safety_issue": "No", 
                "time_frame": "study duration maximum 3,5 years"
            }, 
            {
                "description": "25(OH)D3 serum levels will be recorded at diagnosis and at 6 months intervals up to final study visit. Genetic variability of Vitamin D pathway will be correlated with 25(OH)D3 serum levels", 
                "measure": "25(OH)D3 serum levels", 
                "safety_issue": "No", 
                "time_frame": "study duration maximum 3,5 years"
            }, 
            {
                "description": "Vitamin D levels at diagnosis and genetic variability of the vitamin D pathway will be correlated with stage of melanoma patient at diagnosis according to the 2009 American Joint Committee of Cancer (AJCC) Melanoma staging and classification", 
                "measure": "Stage of melanoma patient", 
                "safety_issue": "No", 
                "time_frame": "study duration maximum 3,5 years"
            }
        ], 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "collaborator": {
                "agency": "Katholieke Universiteit Leuven", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}